Replies to post #252178 on Biotech Values

[vinmantoo]

That deal worked out for me as an investor although it wasn’t a major score for me. If I recall, a worry about Magrolimab was binding to RBCs could cause issues. TRILs Abs were supposed to not have that problem.

I wonder if GILD might be a suitor for VKTX given their interest in the anti-obesity drug area.

[jbog]

Gild has been a dumpster fire as of late. AXL has reported some promising info and I hear nothing about PFE.